ALPCO offers a wide range of testing solutions. Easily expand your GI menu with our portfolio of stool-based biomarker tests, including an FDA Class I Exempt pancreatic elastase assay for use as an aid in the diagnosis of exocrine pancreatic insufficiency (EPI). ALPCO has developed the most clinically accurate fecal calprotectin test on the market. FDA 510(k) cleared and Health Canada licensed, the Calprotectin Chemiluminescence ELISA reduces false positives for IBD from 20-33% to just 7.5%.